Novo Nordisk manufacturing facility, and clients, hit by FDA action
Regulator classifies former Catalent site as ‘official action indicated’, impacting biotech clients such as Regeneron.
List view / Grid view
Regulator classifies former Catalent site as ‘official action indicated’, impacting biotech clients such as Regeneron.
The deal with the US biopharma adds a portfolio of clinical-stage incretin and amylin research programmes to its pipeline.
The company’s CEO says the shift will help prioritise investment into obesity and diabetes, the company’s leading therapy areas.
Advanced technology innovation is driving lower R&D costs and progress of targeted treatments such as cell and gene therapies, the research reports.
Current market conditions in the pharmaceutical industry have driven the change to its executive leadership team, according to Novo Nordisk.
The company now has ABPI membership after a two-year suspension involving concerns relating to its compliance with the industry body’s code of conduct.
Eleven drugs are poised to make waves in the pharmaceutical industry in 2025, according to the annual report.
A total of DKK 8.5 billion will fund the new production facility in Odense, Denmark, which is set to facilitate the manufacture of medicines for rare diseases.
As a promising treatment for type 2 diabetes and obesity, based on key trial data, the market for glucagon-like peptide-1 receptor (GLP-1R) therapies looks set to generate major sales up to 2030.
Biopharma companies that experienced strong revenue growth due to COVID-19 drug sales have been overtaken by companies that developed obesity drugs in 2023, GlobalData suggests.
Novo Nordisk plans to allocate $6.8 billion towards production to expand its overall US manufacturing capacity.
The up to €1bn acquisition of Cardior Pharmaceuticals will strengthen Novo Nordisk’s pipeline in cardiovascular disease.
As part of its acquisition of Catalent, Novo Holdings plans to sell three Catalent fill-finish sites, supporting the growth of the European and US manufacturing capacity.
The facility in Athlone, Ireland, will give Novo Nordisk additional capacity to manufacture oral products.
The new industry collaboration aims to help decarbonise the global supply chain by focusing on the energy-intensive pharmaceutical manufacturing that takes place in China and India.